Stanford University is set to exit the cancer immunotherapy developer, which has filed for a $100m initial public offering.
US-based immuno-oncology drug developer Arcus Biosciences has filed to raise up to $100m in an initial public offering that will allow Stanford University to exit.
Arcus is working on small-molecule and antibody immunotherapies aimed at biological pathways that scientific evidence has suggested play a part in regulating the body’s immune response to cancer.
The proceeds will support the ongoing clinical development of the company’s lead product candidate, AB928, and another candidate, AB122, as well as work on two…
